Business
Faridoxorubicin Program Clinical Updates
Avacta Group PLC has announced significant clinical updates for its faridoxorubicin program, removing the cardiac dosing limit and identifying a path for dose selection in future efficacy studies. This decision stems from highly favorable safety data, allowing patients to receive nearly four times the conventional doxorubicin dose and a maximum cumulative exposure of 550 mg/m² without severe cardiac toxicity. The company will now enroll final Phase 1b cohorts to compare two dose levels, aiming to determine the optimal biologic dose for upcoming efficacy trials, underscoring growing confidence in the tolerability of their pre|CISION® platform. Disclaimer*
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \nAvacta announces two key clinical updates to its faridoxorubicin program\n \nCardiac dosing limit removed and path forward to dose selection identified\n \n \nLONDON and PHILADELPHIA - February 3, 2026 - Avacta Therapeutics (AIM: AVCT, \"the Company\", \"Avacta\"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program.\n \nAgreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin and should support a smooth transition to future efficacy studies.\n \nThe historic maximum dosing limit which is based on the patient's exposure to released (free) doxorubicin, has been removed in the clinical trial following the collection of highly favorable safety data from the faridoxorubicin program and observation of patients receiving the highest cumulative doses for prolonged periods. Dosing in the Phase 1 clinical trial escalated to a dose of nearly 4x the conventional dose of doxorubicin and the maximum cumulative exposure of released doxorubicin was increased to 550 mg/m2 during the trial with no severe cardiac toxicity observed. \n \nOne of the key advantages of the pre|CISION® platform is that its unique delivery mechanism allows patients to receive the drug for longer and at higher doses due to improved tolerability, with the potential to extend the progression free survival endpoint in trials.\n \nThe Company's second significant update relates to the determination of the dose for the study in efficacy trials. The final cohorts of patients with the selected indications in Phase 1b will be enrolled, enabling two dose levels to be compared in order to determine the optimal biologic dose in future trials.\n \nUpdates to the clinical program will appear in the National Library of Medicine's clinicaltrials.gov entry for Faridoxorubicin (AVA6000) under the trial designation, ID Number NCT04969835.\n \nChristina Coughlin, CEO of Avacta Therapeutics commented,\n \n\"These two critical steps in the development of our faridoxor...